Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849251 · ClinicalTrials.gov registry record · Phase 1
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00849251 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 31 participants.
The verdict
NCT00849251, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving pegylated liposomal doxorubicin hydrochloride together with bortezomib, cyclophosphamide, and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects of giving pegylated liposomal doxorubicin hydrochloride together with bortezomib, cyclophosphamide, and dexamethasone and to see how well it works in treating patients with multiple myeloma
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849251
The ClinicalTrials.gov registry entry for NCT00849251 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00849251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00849251 about?
NCT00849251 is a clinical study titled "Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some...
What is the current status of trial NCT00849251?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2008-11. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00849251?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00849251?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.